Arnaud Trebucq

Dr. Arnaud Trebucq


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
ATArnaud Trebucq
Arnaud Trebucq
DED.A. Enarson
D.A. Enarson
CCC.Y. Chiang
C.Y. Chiang
ADA. Van Deun
A. Van Deun
AHA.D. Harries
A.D. Harries
HRH.L. Rieder
H.L. Rieder
Xpert ® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (> 15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.

25 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ATArnaud Trebucq
Arnaud Trebucq
TDTom Decroo
Tom Decroo
ADArmand Van Deun
Armand Van Deun
APAlberto Piubello
Alberto Piubello
CCChen-Yuan Chiang
Chen-Yuan Chiang
VSValérie Schwoebel
Valérie Schwoebel
About ten years ago, the first results of the so-called “Bangladesh regimen”, a short regimen lasting nine months instead of 20 months, revolutionized multidrug-resistant tuberculosis (MDR-TB) treatment. Similar short regimens were studied in different settings, relying for their efficacy on a later generation fluoroquinolone, either gatifloxacin, moxifloxacin, or levofloxacin. We review the published material on short MDR-TB regimens, describe their different compositions, their results in national tuberculosis programs in middle- and low-income countries, the risk of acquiring resistance to fluoroquinolone, and the occurrence of adverse events. With over 80% success, the regimen performs much better than longer regimens (usually around 50%). Monitoring of adverse events allows adapting its composition to prevent severe adverse events such as deafness. We discuss the current applicability and usefulness of the short injectable-containing regimen given the 2019 recommendation of the World Health Organization (WHO) for a new long all-oral regimen. We conclude that the most effective fluoroquinolone is gatifloxacin, currently not listed as an essential medicine by WHO. It is a priority to restore its status as an essential medicine.

1 August 2009
Verified
Journal Article
Closed access
NAN Aït-Khaled
N Aït-Khaled
EAE Alarcon
E Alarcon
KBK Bissell
K Bissell
FBF Boillot
F Boillot
JCJ A Caminero
J A Caminero
NWN Wilson
N Wilson

1 July 2007
Verified
Journal Article
Closed access
CCC-Y Chiang
C-Y Chiang
ATArnaud Trebucq
Arnaud Trebucq
NBN Billo
N Billo
PKP Khortwong
P Khortwong
EEE Elmoghazy
E Elmoghazy
RVR G Vianzon
R G Vianzon

1 December 2015 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
SASerge Ade
Serge Ade
ATArnaud Trebucq
Arnaud Trebucq
Anthony HarriesAnthony Harries
Anthony Harries
GAGabriel Ade
Gabriel Ade
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
SASévérin Anagonou
Sévérin Anagonou
In the “Centre National Hospitalier de Pneumo-Phtisiologie” of Cotonou, Benin, little is known about the characteristics of patients who have not attended their scheduled appointment, the results of tracing and the possible benefits on improving treatment outcomes. This study aimed to determine the contribution of tracing activities for those who missed scheduled appointments towards a successful treatment outcome. A retrospective cohort study was carried out among all smear-positive pulmonary tuberculosis patients treated between January and September 2013. Data on demographic and diagnostic characteristics and treatment outcomes were accessed from tuberculosis registers and treatment cards. Information on those who missed their scheduled appointments was collected from the tracing tuberculosis register. A univariate analysis was performed to explore factors associated with missing a scheduled appointment. Of 457 patients (410 new smear-positive and 47 retreatment tuberculosis), 37 (8 %) missed one or more of their appointments with a total of 44 episodes of missed appointments. The 3.5th (32 %) and 5th (43 %) month appointments were the ones most likely to be missed. Being male was associated with a higher risk of missing appointments (RR = 4.2; 95 % CI = 1.5–11.8, p = 0.004) while having HIV infection was associated with a lower risk (RR = 0.3, 95 % CI = 0.1–0.9, p = 0.03). Principal reasons for missed appointments were travelling outside Cotonou (34 %) and feeling better (21 %). In 24 (55 %) of these 44 episodes of missed appointments, contact was made with the patient who returned to the programme. These follow-up activities increased the treatment success by 4 %. In Cotonou, Benin, less than 10 % of tuberculosis patients miss at least one of their scheduled appointments. Tracing activities increase the treatment success rate by 4 % and current on-going practices in the Programme need to be endorsed and encouraged.

1 October 2004
Verified
Journal Article
Closed access
MGM Gninafon
M Gninafon
LTL Tawo
L Tawo
FKF Kassa
F Kassa
GMG P Monteiro
G P Monteiro
JZJ P Zellweger
J P Zellweger
ATArnaud Trebucq
Arnaud Trebucq